International Cardiovascular Regional Experts Symposia – iCaRE
Message from iCaRE 2017 Chairperson:

“iCaRE is the first CME-accredited platform for communication and collaboration to bring cardiologists and laboratory doctors together under one roof and, ultimately, work together for better patient care across the Middle East. With great opportunities to engage in interactive discussions and collaborative efforts on cardiac biomarkers, iCaRE focused on Cardiac biomarkers to define patient phenotypes and empower clinicians to make decisions that will improve patient care.“

Prof. Abdullah Shehab, MBChB DipMEd MMEd PhD CCST FACP FRCP FESC FACC FSCAI Professor of Cardiovascular Medicine

Our vision

Detailed Agenda

  • Plenary session
    (19:00 - 21:00) Dubai time
    Moderators: Waleed Abdullah Al Habeeb (KSA) & Abdullah Shehab (UAE)
19:00 - 19:10
Welcome
Opening Remarks

Guido Sanders (General Manager, Roche Diagnostics Middle East FZCO)

Introduction to virtual iCaRE 2021

Abdullah Shehab (UAE)

19:10 - 19:45
Session 1 :
NT-proBNP for Heart Failure Risk Stratification in Type II Diabetes and Optimization of Cardioprotective Treatment
Poll Questions about the following presentation

Waleed Abdullah Al Habeeb (KSA)

NT-proBNP for Heart Failure Risk Stratification in Type II Diabetes and Optimization of Cardioprotective Treatment

Antoni Bayes-Genis (Spain)

Q&A

Abdullah Shehab (UAE) & All

19:45 - 20:20
Session 2 :
Role of NT-proBNP in Optimized Acute Heart Failure Management
Poll Questions about the following presentation

Waleed Abdullah Al Habeeb (KSA)

Role of NT-proBNP in Optimized Acute Heart Failure Management

Evangelos Giannitsis (Germany)

Q&A

Abdullah Shehab (UAE) & All

20:20 - 21:00
Session 3 :
Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial
Poll Questions about the following presentation

Waleed Abdullah Al Habeeb (KSA)

Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial

Reza Mohebi (USA)

Q&A

Abdullah Shehab (UAE) & All

Wrap up and recommendations

Waleed Abdullah Al Habeeb (KSA)

  • Saudi Arabia Track
    (19:00 - 21:00) Riyadh time
  • Egypt Track
    (19:00 - 21:00) Cairo time
  • Levant Track
    (19:00 - 21:00) Beirut time
  • Iran Track
    (19:00 - 21:25) Tehran time
19:00 - 19:10
Welcome
Welcome and Introduction to virtual iCaRE 2021 Saudi Arabia Track

Waleed Abdullah Al Habeeb (KSA)

19:10 - 19:45
Session 1 :
HF Burden and Unmet Needs in 2021
Poll Questions about the following presentation

Moderators

HF Burden and Unmet Needs in 2021

Jim Januzzi (USA)

Q&A

All

19:45 - 20:20
Session 2 :
What are the HF Diagnostic challenges in Kingdom of Saudi Arabia area?
Poll Questions about the following presentation

Moderators

What are the HF Diagnostic challenges in Kingdom of Saudi Arabia area?

Kamal Waheeb AIGhalayini (KSA)

Q&A

All

20:20 - 21:00
Session 3 :
What are the Key challenges in the management of HF in Saudi Arabia?
Poll Questions about the following presentation

Moderators

What are the Key challenges in the management of HF in Kingdom of Saudi Arabia?

Maryam AlQaseer (KSA)

Q&A

All

Wrap up and recommendations :- Position Statement/ Saudi Heart Association 5 National Heart Center

Waleed Abdullah Al Habeeb (KSA)

19:00 - 19:10
Welcome
Welcome and Introduction to virtual iCaRE 2021 Egypt Track

Mohamed Ahmed Sobhy Ali Hassan (Egypt)

19:10 - 19:45
Session 1 :
HF Burden and Unmet Needs in 2021
Poll Questions about the following presentation

Moderators

HF Burden and Unmet Needs in 2021

Mahmoud Hassanein (Egypt)

Q&A

All

19:45 - 20:20
Session 2 :
What are the diagnostic challenges in HF?
Poll Questions about the following presentation

Moderators

What are the HF Diagnostic challenges?

Antoni Bayes-Genis (Spain)

Q&A

All

20:20 - 21:00
Session 3 :
What are the Key challenges in the treatment of HF in Egypt?
Poll Questions about the following presentation

Moderators

What are the Key challenges in the management of HF in Egypt?

Mohamed Ahmed Sobhy Ali Hassan (Egypt)

Q&A

All

Wrap up and recommendations :- Peptide for Life

Mohamed Ahmed Sobhy Ali Hassan (Egypt)

19:00 - 19:10
Welcome
Welcome and Introduction to virtual iCaRE 2021 Levant Track

Hadi M. Abu Hantash (Jordan)

19:10 - 19:45
Session 1 :
HF Burden and Unmet Needs in 2021
Poll Questions about the following presentation

Moderators

HF Burden and Unmet Needs in 2021

Evangelos Giannitsis (Germany)

Q&A

All

19:45 - 20:20
Session 2 :
What are the diagnostic challenges in HF in Levant area?
Poll Questions about the following presentation

Moderators

What are the HF Diagnostic challenges in Levant area?

Tony Abdel Massih (Lebanon)

Q&A

All

20:20 - 21:00
Session 3 :
What are the Key challenges in the treatment of HF in Levant area?
Poll Questions about the following presentation

Moderators

What are the Key challenges in the management of HF in Levant area?

Hadi M. Abu Hantash (Jordan)

Q&A

All

Wrap up and recommendations :- Local HF lebanese guidelines

Tony Abdel Massih (Lebanon)

19:00 - 19:10
Welcome
Welcome and Introduction to virtual iCaRE 2021 Iran Track

Babak Sharif Kashani (Iran)

19:10 - 19:45
Session 1 :
HF Burden and Unmet Needs in 2021
Poll Questions about the following presentation

Moderators

HF Burden and Unmet Needs in 2021

Reza Mohebi (USA) & Nasim Naderi (Iran)

Q&A

All

19:45 - 20:20
Session 2 :
What are the diagnostic challenges in HF in Iran?
Poll Questions about the following presentation

Moderators

What are the HF Diagnostic challenges in Iran?

Nasim Naderi (Iran) & Reza Mohebi (USA)

Q&A

All

20:20 - 20:55
Session 3 :
What are the Key challenges in the treatment of HF in Iran?
Poll Questions about the following presentation

Moderators

What are the Key challenges in the management of HF in Iran?

Babak Sharif Kashani (Iran) & Reza Mohebi (USA)

Q&A

All

20:55 - 21:25
Session 4 :
COVID-19 challenges in cardiac management?
Poll Questions about the following presentation

Moderators

COVID-19 challenges in cardiac management

Babak Sharif Kashani (Iran)

Q&A

All

Wrap up and recommendations

Babak Sharif Kashani (Iran) & Reza Mohebi (USA)